Professional Experience Nina Shreve has extensive experience in all aspects of trademark law, including litigation, prosecution, client counseling, opinion work, due diligence investigations and other transactional matters. Ms. Shreve is also active in the firm's patent litigation practice focusing particularly on litigation in the pharmaceutical area. In addition to the pharmaceuticals product area, Ms. Shreve has represented clients in patent and trademark matters in diverse industries, including computers and electronics, consumer healthcare products, industrial machinery and building products. Ms. Shreve is a member of the firm's Diversity Committee. Awards and Recognition Ms. Shreve was listed in Legal 500 2007 in IP-Non-Contentious/Transactional:-- trademarks - full coverage. Nina Shreve and Kristin Blemaster were named recipients of the 2006 Burton Award for Legal Achievement for their article, "Clearing a Trademark for Use," originally published in the May 2005 issue of General Counsel New York. Professional Activities American Bar Association, American Intellectual Property Association; International Trademark Association; New York State Bar Association; New York Intellectual Property Law Association; National Association of Women Lawyers Additional Publications "Clearing a Trademark for Use," General Counsel New York, May 2005 "International Trademark Registration: The Madrid Protocol Takes Effect In The United States," New York Intellectual Property Law Association Bulletin, October/November 2003 "IP for the Hi-Tech Industry," Building and Enforcing Intellectual Property Value: An International Guide for the Boardroom 2003, a Nasdaq and Morgan Stanley publication Representative Matters · Merck against six Canadian internet pharmacies on a patent relating to Merck's cholesterol lowering medication ZOCOR®, and alleging trademark infringement, dilution and unfair competition. · Novartis against Watson Pharmaceuticals and Sun Pharmaceuticals on a patent relating to EXELON®, a leading Alzheimer's disease treatment. · Novartis against Apotex on a patent relating to Novartis' MIACALCIN® calcitonin nasal spray product for osteoporosis. · Novartis against Teva Pharmaceuticals on a patent relating to Novartis' antiviral herpes medication FAMVIR®. Representative Cases Sanofi-Aventis U.S. LLC et al. v. Sun Pharmaceutical Industries Ltd. et al.
D.N.J. 2011 Hoechst GmbH & Sanofi-Aventis Deutschland GmbH v. Genentech, Inc.
ICC International Court of Arbitration 2011 Adams Respiratory Therapeutics, Inc et al. v. Perrigo Company et al.
Fed Cir. 2010 Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A. v. Sandoz, Inc. et al.
Fed. Cir. 2009 Vision-Ease Lens, Inc. v. Essilor International S.A.
D. Minn. 2004 Nabisco v. Warner-Lambert Co.
2d Cir. 2000 Publications Clearing a Trademark for Use
General Counsel New York
May 9, 2005 International Trademark Registration: The Madrid Protocol Takes Effect in the U.S.
2003:The Year in Review Findlaw Corporate Counsel Center
December 2003 IP for the Hi-Tech Industry
Building and Enforcing Intellectual Property Value: An International Guide for the Boardroom 2003
June 2003 Events Practical Guide to U.S. Implementation of the Madrid Protocol
DC Bar CLE Program
October 2003 |